α 1 -Proteinase Inhibitor (Human) in the Treatment of Hereditary Emphysema Secondary to α 1 -Antitrypsin Deficiency: Number and Costs of Years of Life Gained

Author： >   Evans Marc A.   Robison Linda M.   Skaer Tracy L.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.32, Iss.5, 2012-05, pp. : 353-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Flu vax not effective in α1-antitrypsin deficiency

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 547, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Molecular mousetraps, α1-antitrypsin deficiency and the serpinopathies

By Lomas David A  

Clinical Medicine, Vol. 5, Iss. 3, 2005-05 ,pp. : 249-257

Royal College Of Physicians

Access to resources Recommend Favorite

Treatment of 1-antitrypsin deficiency is costly

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 309, 2001-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Treatment of 1-antitrypsin deficiency is costly

By  

Inpharma, Vol. 1, Iss. 1284, 2001-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

The promise of gene therapy for the treatment of αα-1 antitrypsin deficiency

By Cruz Pedro E   Mueller Christian   Flotte Terence R  

Pharmacogenomics, Vol. 8, Iss. 9, 2007-09 ,pp. : 1191-1198

Future Medicine

Access to resources Recommend Favorite